The 4th One Health | Professor Yonghong Xiao: Advancing the One Health Approach to Address Cross-Sector Challenges in Antimicrobial Resistance Control in China

The 4th One Health | Professor Yonghong Xiao: Advancing the One Health Approach to Address Cross-Sector Challenges in Antimicrobial Resistance Control in China

Antimicrobial resistance (AMR) has become a major global public health problem. Resistant bacteria and resistance genes can spread across the human–animal–environment interface through the food chain and the water environment. Relying solely on antimicrobial stewardship within medical institutions makes it difficult to resolve this complex, systemic problem, which is why the integrated One Health prevention and control model is becoming increasingly essential. At the 4th One Health Conference of Antimicrobial Resistance Containment, experts from multiple fields — clinical medicine, animal husbandry, the environment and public health — gathered to discuss the practical dilemmas and development pathways of AMR prevention and control in China. Infectious Disease Frontier invited Professor Yonghong Xiao, Chair of the Conference and of the First Affiliated Hospital, Zhejiang University School of Medicine, for an in-depth conversation covering the value and positioning of the conference, the identification of high-risk resistant pathogens with cross-sector transmission potential, the difficulties of cross-departmental coordination, the building of an integrated surveillance system, and the raising of societal awareness.
ESMO LBA Insights | Balancing Efficacy Gains and Safety Management: A Focus on the DeLLphi-305 and SAFFRON Studies

ESMO LBA Insights | Balancing Efficacy Gains and Safety Management: A Focus on the DeLLphi-305 and SAFFRON Studies

The 2026 European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain, from October 23 to 27. Several major advances in lung cancer research were presented, covering cutting-edge areas such as maintenance therapy for small cell lung cancer (SCLC), precision treatment and perioperative management of non-small cell lung cancer (NSCLC), novel antibody-drug conjugates (ADCs), and immunotherapy-based combination strategies. Although the congress has concluded, academic interest in these findings continues. Oncology Frontier has therefore launched a special series to provide further insights into the key studies and developments presented at the meeting.
CTIC 2026 Chair Interview | Professor He Huang: Driving Innovation Through a Global Perspective and Advancing Development Through Clinical Breakthroughs

CTIC 2026 Chair Interview | Professor He Huang: Driving Innovation Through a Global Perspective and Advancing Development Through Clinical Breakthroughs

Gathering in Qiantang to Discuss Ideas and Shape the Future. From November 6 to 8, 2026, the 2026 Cellular Therapy and Immunotherapy Conference (CTIC 2026) was successfully held in Hangzhou. With a global perspective, the conference brought together leading experts and scholars from China and abroad to explore cutting-edge areas, including cell therapy, gene therapy, AI-enabled hematology, and industrial translation. Participants discussed clinical challenges and explored pathways toward high-quality development in the field. During the conference, Oncology Frontier – Hematology Frontier invited Professor He Huang, Conference Chair, from the First Affiliated Hospital of Zhejiang University School of Medicine, for an in-depth discussion on the conference's academic positioning, clinical challenges in cellular immunotherapy and hematopoietic stem cell transplantation, and the development of young professionals.
ESMO 2026 | Blanca Homet Moreno: New Evidence and Key Questions in Bladder Cancer Treatment — Perioperative Therapy, Patient Selection for Bladder Preservation, and Prospects for ADC-Based Combinations

ESMO 2026 | Blanca Homet Moreno: New Evidence and Key Questions in Bladder Cancer Treatment — Perioperative Therapy, Patient Selection for Bladder Preservation, and Prospects for ADC-Based Combinations

The 2026 European Society for Medical Oncology (ESMO) Congress presented findings from several studies in genitourinary cancers. Among the key topics were differences in the results of studies investigating perioperative chemotherapy combined with immunotherapy, patient selection for bladder-preserving treatment, and emerging approaches combining antibody–drug conjugates (ADCs) with immunotherapy. These developments raise important questions for bladder cancer treatment. How should new evidence influence established clinical perspectives? As treatment options continue to expand, how can clinicians better define individualized treatment pathways for patients? Oncology Frontier – UroStream invited Blanca Homet Moreno, a researcher in the oncology division of Merck & Co., for an interview to share her observations and perspectives on these topics.
ESMO Insights from the East | Professor Jianya Zhou: PD-1/IL-2 Bispecific Antibody Plus Bevacizumab May Offer a New Strategy to Overcome Immunotherapy Resistance in Lung Adenocarcinoma

ESMO Insights from the East | Professor Jianya Zhou: PD-1/IL-2 Bispecific Antibody Plus Bevacizumab May Offer a New Strategy to Overcome Immunotherapy Resistance in Lung Adenocarcinoma

In recent years, immune checkpoint inhibitors (ICIs), particularly those targeting PD-1/PD-L1, have transformed the treatment landscape of advanced driver gene-negative non-small cell lung cancer (NSCLC). However, resistance to immunotherapy remains inevitable. For patients whose disease progresses following first-line immunotherapy combined with chemotherapy, subsequent treatment options are extremely limited, creating an urgent need for more effective strategies to overcome resistance.
ESMO International Perspectives | How Does the BEHOLD-1 Biomarker Analysis Inform Patient Selection for ADC Therapy in Ovarian Cancer?

ESMO International Perspectives | How Does the BEHOLD-1 Biomarker Analysis Inform Patient Selection for ADC Therapy in Ovarian Cancer?

The 2026 European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain, from October 23 to 27. During the Gynecological Cancers Session, an exploratory biomarker analysis from the BEHOLD-1 study attracted considerable attention. The analysis systematically characterized response patterns to Mo-Rez (mocertatug rezetecan), a novel B7-H4-targeted topoisomerase I inhibitor (TOP1i) antibody-drug conjugate (ADC), in patients with platinum-resistant ovarian cancer (PROC). The findings showed that 96% of patients with PROC had B7-H4-positive tumors, while clinical responses to Mo-Rez were observed across different levels of B7-H4 expression. The linker-cleaving enzyme CTSB, the payload sensitivity gene TOP1, stromal remodeling, and immune-related pathways were all associated with response.
Breaking New Ground | ORR of 68% and mPFS of 11.2 Months! Sacituzumab Tirumotecan Plus Immunotherapy Explores a New First-Line Treatment Strategy for la/mUC

Breaking New Ground | ORR of 68% and mPFS of 11.2 Months! Sacituzumab Tirumotecan Plus Immunotherapy Explores a New First-Line Treatment Strategy for la/mUC

In recent years, the combination of antibody-drug conjugates (ADCs) and immunotherapy has transformed the treatment landscape for locally advanced or metastatic urothelial carcinoma (la/mUC). However, for patients who are ineligible for cisplatin, improving tumor response rates, prolonging disease control, and maintaining treatment tolerability and quality of life remain important clinical challenges. At the 2026 European Society for Medical Oncology (ESMO) Congress, a study of first-line treatment with a regimen combining China's homegrown TROP2 ADC sacituzumab tirumotecan and immunotherapy in la/mUC was presented in a Rapid Oral session [1]. Updated data showed a confirmed objective response rate (ORR) of 68%, a median duration of response (mDOR) of 19.4 months, and a median progression-free survival (mPFS) of 11.2 months. Effective and durable tumor responses were observed regardless of TROP2 or PD-L1 expression levels, providing important evidence to inform clinical treatment decisions. Oncology Frontier – UroStream invited Professor Dingwei Ye and Professor Xiaojie Bian of Fudan University Shanghai Cancer Center to discuss the study design, efficacy and safety findings, and the development of Chinese-originated ADCs in genitourinary oncology, with the aim of providing insights for clinical practice.
ESMO Voices from China | Landmark Study Led by Academician Binghe Xu Published in The Lancet: Iza-bren Reshapes the Breast Cancer Treatment Landscape with Robust Clinical Data

ESMO Voices from China | Landmark Study Led by Academician Binghe Xu Published in The Lancet: Iza-bren Reshapes the Breast Cancer Treatment Landscape with Robust Clinical Data

At the 2026 European Society for Medical Oncology (ESMO) Congress, the PANKU-Breast01 study, led by Academician Binghe Xu of the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences, was presented as a late-breaking abstract (LBA) and simultaneously published in the internationally renowned medical journal The Lancet (impact factor: 109). In the more than 200-year history of The Lancet, this is the first study of an innovative Chinese drug in the breast cancer field to be published in the journal's flagship edition.